The Leukemia & Lymphoma Society of Canada's (LLSC's) research programs are creating tomorrow's treatments and laying the groundwork for the ultimate cures. Highlights include:
- Operating Grants provides funds to Canadian investigators whose work is innovative and highly regarded by others in the scientific community.
- The Therapy Acceleration Program, launched in 2007 and based out of the LLS in the US, helps speed blood cancer research along during what can be an otherwise slow-moving process. It's helped bring more treatments to more patients faster.
The program helps promising new treatments reach patients quickly by:
- providing the funding and support needed to help researchers bring their projects closer to the product stage
- funding projects within biotechnology companies on the cutting-edge of blood cancer therapies
- helping patients gain easier access to clinical trials by working to overcome obstacles that may prevent them from participating, such as inconvenient locations and lack of insurance coverage
- Celator Phase 3 Trial for VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia.The clinical trial was conducted in partnership with The Leukemia & Lymphoma Society®(LLS) through its Therapy Acceleration Program (TAP), which has supported the clinical development of VYXEOS beginning in Phase 2.
Canadian researchers can also apply for grants from The Leukemia & Lymphoma Society in the United States. More information on their program can be found here. You will be transferred to the website of The Leukemia & Lymphoma Society in the United States.